Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

326 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial.
Strand V, Kosinski M, Chen CI, Joseph G, Rendas-Baum R, Graham NM, van Hoogstraten H, Bayliss M, Fan C, Huizinga T, Genovese MC. Strand V, et al. Among authors: chen ci. Arthritis Res Ther. 2016 Sep 6;18(1):198. doi: 10.1186/s13075-016-1096-9. Arthritis Res Ther. 2016. PMID: 27600829 Free PMC article. Clinical Trial.
Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors.
Strand V, Reaney M, Chen CI, Proudfoot CW, Guillonneau S, Bauer D, Mangan E, Graham NM, van Hoogstraten H, Lin Y, Pacheco-Tena C, Fleischmann R. Strand V, et al. Among authors: chen ci. RMD Open. 2017 Mar 7;3(1):e000416. doi: 10.1136/rmdopen-2016-000416. eCollection 2017. RMD Open. 2017. PMID: 28326189 Free PMC article.
Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.
Strand V, Gossec L, Proudfoot CWJ, Chen CI, Reaney M, Guillonneau S, Kimura T, van Adelsberg J, Lin Y, Mangan EK, van Hoogstraten H, Burmester GR. Strand V, et al. Among authors: chen ci. Arthritis Res Ther. 2018 Jun 19;20(1):129. doi: 10.1186/s13075-018-1614-z. Arthritis Res Ther. 2018. PMID: 29921318 Free PMC article. Clinical Trial.
Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies.
Ferrufino CP, Munakata J, Wei W, Proudfoot C, Kuznik A, Boklage SH, Chen CI. Ferrufino CP, et al. Among authors: chen ci. Clinicoecon Outcomes Res. 2018 Nov 16;10:805-819. doi: 10.2147/CEOR.S163829. eCollection 2018. Clinicoecon Outcomes Res. 2018. PMID: 30532571 Free PMC article.
Sarilumab monotherapy compared with adalimumab monotherapy for the treatment of moderately to severely active rheumatoid arthritis: an analysis of incremental cost per effectively treated patient.
Fournier M, Chen CI, Kuznik A, Proudfoot C, Mallya UG, Michaud K. Fournier M, et al. Among authors: chen ci. Clinicoecon Outcomes Res. 2019 Feb 5;11:117-128. doi: 10.2147/CEOR.S183076. eCollection 2019. Clinicoecon Outcomes Res. 2019. PMID: 30787625 Free PMC article.
Indirect Treatment Comparison of the Efficacy and Safety of Sarilumab Monotherapy in Rheumatoid Arthritis Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs.
Choy E, Freemantle N, Proudfoot C, Chen CI, Pollissard L, Kuznik A, van Hoogstraten H, Mangan E, Carita P, Huynh TM. Choy E, et al. Among authors: chen ci. Adv Ther. 2019 Apr;36(4):817-827. doi: 10.1007/s12325-019-00912-x. Epub 2019 Mar 12. Adv Ther. 2019. PMID: 30864105 Free PMC article.
326 results